CR11737A - MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME - Google Patents

MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME

Info

Publication number
CR11737A
CR11737A CR11737A CR11737A CR11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A
Authority
CR
Costa Rica
Prior art keywords
factor
modified
polypeptides
polipeptides
same
Prior art date
Application number
CR11737A
Other languages
Spanish (es)
Inventor
Alan Brooks
John E Murphy
Marian Seto
Xiaoqiao Jian
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Original Assignee
Bayer Schering Pharma Ag
Bayer Healthcare Llc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Bayer Healthcare Llc, Schering Corp filed Critical Bayer Schering Pharma Ag
Publication of CR11737A publication Critical patent/CR11737A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan polipéptidos modificados del factor IX, tales como los polipéptidos del factor IX con uno o más sitios de glicosilación introducidos. Los polipéptidos modificados del factor IX pueden exhibir un incremento de la estabilidad in vitro o in vivo, tal como una semivida plasmática más prolongada. Asimismo se divulgan procedimientos de fabricar polipéptidos modificados del factor IX y a procedimientos de usar modificados del factor IX para, por ejemplo, tratar a pacientes afectados por hemofilia B.Modified factor IX polypeptides, such as factor IX polypeptides with one or more glycosylation sites introduced are disclosed. Modified factor IX polypeptides may exhibit increased stability in vitro or in vivo, such as a longer plasma half-life. Methods of manufacturing modified factor IX polypeptides and methods of using modified factor IX are also disclosed to, for example, treat patients affected by hemophilia B.

CR11737A 2008-04-16 2010-10-15 MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME CR11737A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US4596108P 2008-04-17 2008-04-17

Publications (1)

Publication Number Publication Date
CR11737A true CR11737A (en) 2011-02-07

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11737A CR11737A (en) 2008-04-16 2010-10-15 MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME

Country Status (17)

Country Link
EP (1) EP2288622A4 (en)
JP (1) JP2011517951A (en)
KR (1) KR20110005862A (en)
CN (1) CN102083856A (en)
AU (1) AU2009244633A1 (en)
BR (1) BRPI0910702A2 (en)
CA (1) CA2721683A1 (en)
CO (1) CO6311000A2 (en)
CR (1) CR11737A (en)
DO (1) DOP2010000311A (en)
EC (1) ECSP10010551A (en)
IL (1) IL208718A0 (en)
MX (1) MX2010011345A (en)
RU (1) RU2010146387A (en)
SG (1) SG189790A1 (en)
SV (1) SV2010003704A (en)
WO (1) WO2009137254A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423306A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
CN104004739A (en) * 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 Human factor IX variants with an extended half life
FI3581650T3 (en) 2008-09-15 2023-03-23 Uniqure Biopharma B V Factor ix polypeptide mutant, its uses and a method for its production
NZ605348A (en) 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
TWI595004B (en) * 2010-11-03 2017-08-11 介控生化科技公司 Modified factor ix polypeptides and uses thereof
SI2717898T1 (en) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
WO2013162078A1 (en) * 2012-04-27 2013-10-31 学校法人日本大学 Therapeutic agent for injury in epithelium and endothelium
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US20150252345A1 (en) 2012-09-25 2015-09-10 Biogen Idec Ma Inc. Methods of Using FIX Polypeptides
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
ES2959747T3 (en) 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Optimized factor VIII gene
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
HUE057005T2 (en) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EP4332839A3 (en) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EP3123090A4 (en) 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Lyophilized factor ix formulations
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
TWI741992B (en) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 Factor ix fusion proteins and methods of making and using same
HRP20221089T1 (en) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimized factor viii genes
CN105695616A (en) * 2016-04-22 2016-06-22 王冬国 Analysis marker for diagnosing thyroid cancer and application thereof
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
AU2018215092A1 (en) 2017-01-31 2019-08-29 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
FR3069540B1 (en) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 MODIFIED PROTEIN WITH IMPROVED HALF-LIFE
US20210163986A1 (en) 2017-08-09 2021-06-03 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US20200263196A1 (en) 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
RU2020136050A (en) 2018-04-04 2022-05-06 Сайджилон Терапьютикс, Инк. IMPLANTABLE PARTICLES AND CORRESPONDING METHODS
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
JP2021523878A (en) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド How to treat hemophilia A
US20200069817A1 (en) 2018-08-09 2020-03-05 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
JP2022531095A (en) 2019-04-17 2022-07-06 コディアック バイオサイエンシーズ， インコーポレイテッド Exosomes and AAV compositions
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
EP4298737A1 (en) 2021-02-24 2024-01-03 BlueHalo LLC System and method for a digitally beamformed phased array feed
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (en) * 1988-11-09 1991-04-12 Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
EP1427820A2 (en) * 2001-09-04 2004-06-16 MERCK PATENT GmbH Modified factor ix
MXPA05010846A (en) * 2003-04-09 2006-03-30 Nektar Therapeutics Hemophilia treatment by inhalation of coagulation factors.
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0417341A (en) * 2003-12-03 2007-04-17 Neose Technologies Inc glyceguiled factor ix
EP2423306A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
CO6311000A2 (en) 2011-08-22
BRPI0910702A2 (en) 2016-07-05
SG189790A1 (en) 2013-05-31
CA2721683A1 (en) 2009-11-12
EP2288622A4 (en) 2012-04-18
EP2288622A2 (en) 2011-03-02
RU2010146387A (en) 2012-05-27
IL208718A0 (en) 2010-12-30
SV2010003704A (en) 2011-02-21
KR20110005862A (en) 2011-01-19
MX2010011345A (en) 2011-02-23
DOP2010000311A (en) 2011-02-28
WO2009137254A3 (en) 2010-01-14
ECSP10010551A (en) 2010-11-30
AU2009244633A1 (en) 2009-11-12
JP2011517951A (en) 2011-06-23
WO2009137254A2 (en) 2009-11-12
CN102083856A (en) 2011-06-01

Similar Documents

Publication Publication Date Title
CR11737A (en) MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME
CR20120052A (en) MODIFIED FACTOR IX POLIPEPTIDES AND USES OF THE SAME
DOP2016000042A (en) ANTIBODIES AGAINST THE TYPE 1 (PAI-1) PLASMINOGEN ACTIVATOR INHIBITOR AND USES OF THE SAME
IN2014DN09782A (en)
CO6331368A2 (en) MODIFIED POLIPEPTIDE FACTORS VII (FVII)
UY32966A (en) OCTAHYDROPIRROLO (3,4-C) DISPOSED PIRROLS AS MODULATORS OF THE OREXINE RECEIVER
BRPI0920914A8 (en) ALPHA-KETO PERACIDS AND METHODS FOR PRODUCING AND USING THEM.
CR20140512A (en) DEVICES AND METHODS FOR THE MANUFACTURE OF IMPLANT COMPONENT ADDITIVES
SV2009003393A (en) FACTOR POLIPEPTIDES VII MODIFICATIONS AND USES OF THE SAME
AR084057A1 (en) COMPOSITIONS FOR FABRIC CARE
WO2012106281A3 (en) Multimodal trail molecules and uses in cellular therapies
BR112014012524A2 (en) compositions comprising a shelf life stability component
CR20110630A (en) CARBOXAMIDE COMPOUNDS AND ITS USE AS CALPAIN INHIBITORS
CR11866A (en) DERIVATIVES OF PIRIDINO-PIRIDINONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
GT200900309A (en) DERIVATIVES OF 7-ALQUINIL-1,8-NAFTIRIDONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
DOP2010000251A (en) EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL
IN2014DN06104A (en)
UY29361A1 (en) PIRROLES AND IMIDAZOLS REPLACED, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE
PA8796001A1 (en) HISTAMINE H4-FURO-PYRIMIDINE MODULATORS OF THE H4 HISTAMINE RECEIVER
MX2012001409A (en) Modified agrin-fragment capable of restoring muscle strength for use as a medicament.
BR112014016803A8 (en) macrocyclic amides as protease inhibitors
ECSP13012613A (en) METHOD FOR PRODUCING AND USING A SOUND CARBOXIMETILCELLULOSE AND GOSIPOL COPOLYMER
UY29371A1 (en) PIRROLES REPLACED, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCESS
EA201390350A1 (en) REMEDIAL MEANS CONTAINING POLYETHYLENE GLYCOL AND ELECTROLYTES
EA201590782A1 (en) ОКСИРАНОВЫЕ АМИНЫ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)